<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134487">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01900379</url>
  </required_header>
  <id_info>
    <org_study_id>1310</org_study_id>
    <secondary_id>2013-A00543-42</secondary_id>
    <nct_id>NCT01900379</nct_id>
  </id_info>
  <brief_title>PAC-IC-SAOS Obstructive Sleep Apnea Syndrome and Ventricular Function</brief_title>
  <acronym>PAC-IC-SAOS</acronym>
  <official_title>Impact of the Obstructive Sleep Apnea Syndrome Treatment and Ventricular Function in Heart Failure Patients Undergoing Coronary Artery Bypass Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this clinical trial is to evaluate the effect of obstructive sleep apnea syndrome
      (OSAS)  treatment in heart failure patients following coronary artery bypass graft (CABG)
      surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial is a double-blind, randomized, placebo-controlled study.

      The first objective is to evaluate the influence of continuous positive airway pressure
      (CPAP) treatment for OSAS on the ventricular function improvement in heart failure patients,
      in comparison with OSA patients treated with sham CPAP. This treatment will be instaurated
      just after CABG surgery

      Secondary objectives :

        -  Evaluation of the effect of CPAP treatment on the endothelial function

        -  Evaluation of the effect of CPAP treatment on systemic inflammation

        -  Evaluation of the effect of CPAP treatment on oxidative stress,

        -  Evaluation of the effect of CPAP treatment on insulin resistance,

      after the CABG surgery, in comparison with OSA patients treated with sham CPAP and non
      apneic control patients, with heart failure.

        -  Assessment of the impact of nocturnal desaturation level on the vascular reactivity and
           atherosclerosis of mammary vessels collected during surgery.

        -  Assessment of the impact of nocturnal desaturation level on the oxidative stress,
           inflammation and insulin sensitivity on abdominal and epicardiac adipose tissue
           collected during surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percent of ventricular function recovery (left ventricular ejection fraction (LVEF)) improvement conferred by CPAP post-operative treatment</measure>
    <time_frame>After 3 months of CPAP post-operative treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Measurement of the left ventricular ejection fraction by a cardiac ultrasonography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of CPAP effect on the endothelial function, after the surgery in comparison with sham CPAP treated patient with heart failure and OSAS.</measure>
    <time_frame>After 3 months of CPAP post-operative treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Measurement of peripheral arterial tone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of CPAP effect on the endothelial function, after the surgery in comparison with sham CPAP treated patient with heart failure and OSAS.</measure>
    <time_frame>After 3 months of CPAP post-operative treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Measurement of pulse wave velocity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the impact of nocturnal desaturation level on the vascular atherosclerosis of mammary vessels collected during surgery.</measure>
    <time_frame>Sleep disordered breathing level, 2 months before surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>By immunological and histological analysis of mammary vessels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the impact of nocturnal desaturation level on the oxidative stress, inflammation and insulin sensitivity of the abdominal and epicardiac adipose tissue collected during surgery.</measure>
    <time_frame>Sleep disordered breathing level, 2 months before surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Measuring inflammatory and oxidative adipose markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the impact of nocturnal desaturation level on the vascular reactivity of mammary vessels collected during surgery.</measure>
    <time_frame>Sleep disordered breathing level, 2 months before surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>By immunological and histological analysis of abdominal and epicardiac adipose tissue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of CPAP effect on the systemic inflammation and oxidative stress, the insulin resistance, after the surgery in comparison with sham CPAP treated patients with heart failure and OSAS.</measure>
    <time_frame>After 3 months of CPAP post-operative treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Measurement of inflammatory and oxidative serum markers</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">69</enrollment>
  <condition>Heart Failure</condition>
  <condition>Arteriosclerosis of Coronary Artery Bypass Graft</condition>
  <condition>Sleep Apnea, Obstructive</condition>
  <arm_group>
    <arm_group_label>OSA/CPAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OSA patients intervention : CPAP treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OSA/sham CPAP</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>OSA patients intervention : Sham CPAP treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients without any apnea syndrome</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CPAP treatment</intervention_name>
    <description>This device consists in a nasal continuous positive airway pressure. It will be applied just after CABG and for 3 months for OSA/CPAP patients group.</description>
    <arm_group_label>OSA/CPAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham CPAP treatment</intervention_name>
    <description>This device consists in a sham continuous positive airway pressure. It will be applied just after CABG and for 3 months for OSA/sham CPAP patients group.</description>
    <arm_group_label>OSA/sham CPAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Coronary Artery Bypass Surgery

          -  Heart failure patient: with visual LVEF &lt;45% by echocardiogram

        Exclusion Criteria:

          -  Aortic or mitral valvular replacement

          -  Aortic surgery

          -  Triple stimulator implanted less than 6 months ago

          -  Patient already treated for a SAOS syndrome

          -  Patient with a central sleep apnea syndrome

          -  Patient with malignant evolutive pathology

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renaud TAMISIER, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Grenoble, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Renaud TAMISIER, MD, PhD</last_name>
    <phone>33-476-765-516</phone>
    <email>RTamisier@chu-grenoble.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital of Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renaud TAMISIER, MD, PhD</last_name>
      <phone>33-476-765-516</phone>
      <email>RTamisier@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Sandrine LAUNOIS-ROLLINAT, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick LEVY, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Louis PEPIN, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent BACH, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier CHAVANON, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rachid HACINI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paolo PORCU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Philippe BAGUET, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles BARONE-ROCHETTE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carole SAUNIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile ROCCA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrice FAURE, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Françoise STANKE, PharmD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>November 28, 2013</lastchanged_date>
  <firstreceived_date>July 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obstructive sleep apneas syndrome</keyword>
  <keyword>Continuous positive airway pressure treatment</keyword>
  <keyword>Heart failure</keyword>
  <keyword>Coronary artery bypass graft surgery</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
